Chris Mueller is an associate professor in the department of pediatrics at the University of Massachusetts Medical School (UMMS).
Chris has published extensively on adeno-associated viral (AAV) gene therapy tools and therapeutic approaches for genetic disorders of the lung, liver and central nervous system. Notably, Chris and collaborators have advanced AAV gene therapy translational research projects for alpha-1 antitrypsin deficiency (A1AT) through phase 2b trials, and through preclinical development for Huntington’s Disease and Amyotrophic Lateral Sclerosis (ALS). Chris’ work uses tools including dual function vectors, artificial miRNAs, and Crispr/Cas9 and modified AAV capsids to develop new therapeutic approaches. In addition to his role at UMMS, he also serves as Chief Scientific Officer at Apic Bio, a preclinical-stage gene therapy company based in Cambridge, Mass.
Chris earned his undergraduate degree from the Florida Institute of Technology, his doctorate in genetics from the University of Florida and his masters in clinical investigation from the University of Massachusetts.